Docoh
Loading...

HGEN Humanigen

APP
Utility
Methods of Treating Immunotherapy-related Toxicity Using a GM-CSF Antagonist
21 Oct 21
Methods for neutralizing and/or removing human GM-CSF in a subject in need thereof, comprising administering to the subject CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells) are provided.
Cameron Durrant, Dale Chappell
Filed: 19 Apr 21
APP
Utility
Methods for Treating Coronavirus Infection and Resulting Inflammation-induced Lung Injury
7 Oct 21
The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.
Cameron DURRANT, Dale CHAPPELL
Filed: 29 Mar 21
GRANT
Utility
Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
28 Sep 21
Methods for reducing blood-brain barrier disruption in a subject treated with immunotherapy, the method comprising administering a recombinant GM-CSF antagonist to the subject.
Cameron Durrant, Dale Chappell
Filed: 22 Feb 19
APP
Utility
Methods of Treating Immunotherapy-related Toxicity Using a GM-CSF Antagonist
23 Sep 21
Methods for neutralizing and/or removing human GM-CSF in a subject in need thereof, comprising administering to the subject CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells) are provided.
Cameron DURRANT, Dale CHAPPELL
Filed: 10 Sep 19
APP
Utility
Materials and Methods for Treating Cancer
16 Sep 21
This document provides methods and materials involved in treating cancer.
Cameron DURRANT, Dale CHAPPELL, Saad J. KENDERIAN, Michelle J. COX, Reona SAKEMURA
Filed: 22 Mar 21
APP
Utility
Methods of Treating Immunotherapy-related Toxicity Using a GM-CSF Antagonist
2 Sep 21
Methods for reducing relapse rate or preventing occurrence of tumor relapse in a subject treated with immunotherapy, in an absence of an incidence of immunotherapy-related toxicity or in a presence of immunotherapy-related toxicity.
Cameron DURRANT, Dale Chappell
Filed: 16 Jan 21
APP
Utility
EPHA3 Directed Car-t Cells for Treatment of Tumors
12 Aug 21
This invention provides chimeric antigen receptors (CARs) targeting human EphA3 and dual targeting CARs that bind to human EphA3 and to human mutant epidermal growth factor receptor variant III (EGFRvIII).
Cameron DURRANT, Dale CHAPPELL, Saad J. KENDERIAN
Filed: 9 Nov 20
APP
Utility
Methods of Treating Immunotherapy-related Toxicity Using a GM-CSF Antagonist
29 Jul 21
Methods for reducing relapse rate or preventing occurrence of tumor relapse in a subject treated with immunotherapy, in an absence of an incidence of immunotherapy-related toxicity or in a presence of immunotherapy-related toxicity.
Cameron DURRANT, Dale CHAPPELL
Filed: 27 Jan 21
APP
Utility
Methods of Treating Immunotherapy-related Toxicity Using a GM-CSF Antagonist
6 May 21
Methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject, the method comprising a step of administering a recombinant hGM-CSF antagonist to the subject, wherein said administering inhibits or reduces the incidence or the severity of immunotherapy-related toxicity in said subject, are provided.
Cameron DURRANT, Dale CHAPPELL
Filed: 13 Nov 20
GRANT
Utility
Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
23 Feb 21
Methods for reducing relapse rate or preventing occurrence of tumor relapse in a subject treated with immunotherapy, in an absence of an incidence of immunotherapy-related toxicity or in a presence of immunotherapy-related toxicity.
Cameron Durrant, Dale Chappell
Filed: 15 Jan 19
GRANT
Utility
Immunoglobulin variable region cassette exchange
16 Feb 21
The invention provides methods for generating human antibodies with the specificity of a reference antibody by replacement of portions of the VH and VL sequences of the reference antibody with sequences from human antibody repertoires.
Christopher Robert Bebbington, Kenneth R. Luehrsen, Geoffrey T. Yarranton
Filed: 14 Dec 15
GRANT
Utility
Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
26 Jan 21
Methods for reducing relapse rate or preventing occurrence of tumor relapse in a subject treated with immunotherapy, in an absence of an incidence of immunotherapy-related toxicity or in a presence of immunotherapy-related toxicity.
Cameron Durrant, Dale Chappell
Filed: 29 Nov 18
GRANT
Utility
Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
21 Dec 20
Methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject, the method comprising a step of administering a recombinant hGM-CSF antagonist to the subject, wherein said administering inhibits or reduces the incidence or the severity of immunotherapy-related toxicity in said subject, are provided.
Cameron Durrant, Dale Chappell
Filed: 1 Oct 18
APP
Utility
Methods of Treating Immunotherapy-related Toxicity Using a GM-CSF Antagonist
11 Nov 20
Methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject, the method comprising a step of administering a recombinant hGMCSF antagonist to the subject, wherein said administering inhibits or reduces the incidence or the severity of immunotherapy-related toxicity in said subject, are provided.
Cameron DURRANT, Dale CHAPPELL
Filed: 1 Oct 18
APP
Utility
Methods of Treating Immunotherapy-related Toxicity Using a GM-CSF Antagonist
6 Nov 19
Methods for reducing relapse rate or preventing occurrence of tumor relapse in a subject treated with immunotherapy, in an absence of an incidence of immunotherapy-related toxicity or in a presence of immunotherapy-related toxicity.
Cameron DURRANT, Dale Chappell
Filed: 14 Jan 19
APP
Utility
Methods of Treating Immunotherapy-related Toxicity Using a GM-CSF Antagonist
23 Oct 19
Methods for reducing blood-brain barrier disruption in a subject treated with immunotherapy, the method comprising administering a recombinant GM-CSF antagonist to the subject.
Cameron Durrant, Dale CHAPPELL
Filed: 21 Feb 19
  • 1
Patents are sorted by USPTO publication date, most recent first